Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henry G Bone

Showing results (31-40 of 55) with videos related to

Pageof 6
Sort By:
The Journal of Family Planning and Reproductive Health Care|September 25, 2013
Comment on journal review of 'Use of depot medroxyprogesterone acetate contraception and incidence of bone fracture'Lee L Lanza, Lisa J McQuay, Kenneth J Rothman, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|October 31, 2009
Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone densityHenry G Bone, Michael R McClung, Christian Roux, et al.
Obstetrics and Gynecology|May 3, 2013
Use of depot medroxyprogesterone acetate contraception and incidence of bone fractureLee L Lanza, Lisa J McQuay, Kenneth J Rothman, et al.
The Journal of Clinical Endocrinology and Metabolism|August 14, 2003
Pins and plaster aren't enough: a call for the evaluation and treatment of patients with osteoporotic fracturesEthel S Siris, John P Bilezikian, Mishaela R Rubin, et al.
Annals of Internal Medicine|March 7, 2007
Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trialSusan L Greenspan, Henry G Bone, Mark P Ettinger, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 10, 2017
Safety Observations With 3 Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab During the Randomized FREEDOM Trial and Subjects Who Crossed Over to Denosumab During the FREEDOM ExtensionNelson B Watts, Jacques P Brown, Socrates Papapoulos, et al.
BMC Musculoskeletal Disorders|April 29, 2017
Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension studyJonathan D Adachi, Henry G Bone, Nadia S Daizadeh, et al.
The New England Journal of Medicine|March 19, 2004
Ten years' experience with alendronate for osteoporosis in postmenopausal womenHenry G Bone, David Hosking, Jean-Pierre Devogelaer, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|April 26, 2018
Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group StudyMichael R McClung, Jacques P Brown, Adolfo Diez-Perez, et al.
Calcified Tissue International|April 2, 2008
Sequestosome 1 (SQSTM1) mutations in Paget's disease of bone from the United StatesEmily C Rhodes, Teresa L Johnson-Pais, Frederick R Singer, et al.
Pageof 6

Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
The Journal of Family Planning and Reproductive Health Care|September 25, 2013
Comment on journal review of 'Use of depot medroxyprogesterone acetate contraception and incidence of bone fracture'Lee L Lanza, Lisa J McQuay, Kenneth J Rothman, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|October 31, 2009
Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone densityHenry G Bone, Michael R McClung, Christian Roux, et al.
Obstetrics and Gynecology|May 3, 2013
Use of depot medroxyprogesterone acetate contraception and incidence of bone fractureLee L Lanza, Lisa J McQuay, Kenneth J Rothman, et al.
The Journal of Clinical Endocrinology and Metabolism|August 14, 2003
Pins and plaster aren't enough: a call for the evaluation and treatment of patients with osteoporotic fracturesEthel S Siris, John P Bilezikian, Mishaela R Rubin, et al.
Annals of Internal Medicine|March 7, 2007
Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trialSusan L Greenspan, Henry G Bone, Mark P Ettinger, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 10, 2017
Safety Observations With 3 Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab During the Randomized FREEDOM Trial and Subjects Who Crossed Over to Denosumab During the FREEDOM ExtensionNelson B Watts, Jacques P Brown, Socrates Papapoulos, et al.
BMC Musculoskeletal Disorders|April 29, 2017
Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension studyJonathan D Adachi, Henry G Bone, Nadia S Daizadeh, et al.
The New England Journal of Medicine|March 19, 2004
Ten years' experience with alendronate for osteoporosis in postmenopausal womenHenry G Bone, David Hosking, Jean-Pierre Devogelaer, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|April 26, 2018
Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group StudyMichael R McClung, Jacques P Brown, Adolfo Diez-Perez, et al.
Calcified Tissue International|April 2, 2008
Sequestosome 1 (SQSTM1) mutations in Paget's disease of bone from the United StatesEmily C Rhodes, Teresa L Johnson-Pais, Frederick R Singer, et al.
Pageof 6